ACACB could regulate the sensitivity of CRC cells to cetuximab, which might be related to EGFR phosphorylation, the activation of the mTOR/Akt signaling pathway, and the regulation of CDT1, cyclin D1, and p21 which are related to cell cycle modulation. Here, AKT1 is linked to colorectal carcinoma.